• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

    7/11/24 8:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary
    Get the next $EVH alert in real time by email

    Company to Participate in Upcoming Conferences

    WASHINGTON, July 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close, with a conference call to follow at 5 p.m. ET.

    Evolent Health Logo (PRNewsfoto/Evolent Health)

    Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com.

    Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolent call" 15 minutes prior to the call.

    An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call.

    Upcoming Investor Events

    Additionally, The Company announced that its executive management team will participate in upcoming investor conferences.



    A live audio-only webcast and replay for these events will be available, if applicable, on the investor relations section of Evolent's website, unless otherwise noted below.

    • Canaccord Genuity 44th Annual Growth Conference at the InterContinental Boston Hotel, Boston, Massachusetts, on August 13, 2024. A live broadcast of management's presentation will take place at 8:30 a.m. ET.
    • 2024 Bernstein Disruptor Conference at the Alliance Bernstein Offices Midtown in New York, New York, on September 24, 2024. A live webcast, if available, will be posted to Evolent's investor relations website.   

    About Evolent 



    Evolent specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting https://ir.evolent.com.

    Contacts:

    Seth R. Frank

    Vice President, Investor Relations

    Evolent

    [email protected]

    571-895-3919 (W)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-to-release-second-quarter-2024-financial-results-on-thursday-august-8-2024-302194326.html

    SOURCE Evolent Health, Inc.

    Get the next $EVH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVH

    DatePrice TargetRatingAnalyst
    1/10/2025$15.00Buy
    Needham
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    4/22/2024$40.00Buy
    Citigroup
    3/1/2024$45.00Outperform
    Oppenheimer
    1/3/2024$39.00Overweight
    Barclays
    More analyst ratings